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Community-specific antimicrobial susceptibility data
may help monitor trends among drug-resistant
Streptococcus pneumoniae and guide empiric therapy.
Because active, population-based surveillance for invasive
pneumococcal disease is accurate but resource intensive,
we compared the proportion of penicillin-nonsusceptible
isolates obtained from existing antibiograms, a less expen-
sive system, to that obtained from 1 year of active surveil-
lance for Georgia, Tennessee, California, Minnesota,
Oregon, Maryland, Connecticut, and New York. For all
sites, proportions of penicillin-nonsusceptible isolates from
antibiograms were within 10 percentage points (median
3.65) of those from invasive-only isolates obtained through
active surveillance. Only 23% of antibiograms distin-
guished between isolates intermediate and resistant to
penicillin; 63% and 57% included susceptibility results for
erythromycin and extended-spectrum cephalosporins,
respectively. Aggregating existing hospital antibiograms is
a simple and relatively accurate way to estimate local
prevalence of penicillin-nonsusceptible pneumococcus;
however, antibiograms offer limited data on isolates with
intermediate and high-level penicillin resistance and iso-
lates resistant to other agents.
I
nfections from Streptococcus pneumoniae tax the
healthcare system in the United States and other coun-
tries. Scientific advances have been made in the treatment
and prevention of pneumococcal infections through antibi-
otics and licensure of vaccines for both adults and chil-
dren; however, the last few decades have witnessed the
emergence of S. pneumoniae resistance to antibiotics (1).
In a multistate, population-based surveillance system that
follows invasive disease from pneumococcus and other
bacterial pathogens, the percent of isolates resistant to
penicillin reached 24% in 1998; concurrent increases in
resistance to other antimicrobial drugs have also been
noted among penicillin-resistant pneumococci (1,2).
Implications of drug-resistance extend beyond the labora-
tory and into clinical practice as treatment failures from
drug resistance have been reported with meningitis (3–5)
and otitis media (6,7). In some studies, increased death and
disease in patients hospitalized with pneumonia caused by
high-level  β-lactam-resistant pneumococci have been
reported (8,9).
Measuring pneumococcal resistance to penicillin and
other antibiotics enables epidemiologists and healthcare
providers to monitor trends, develop guidelines for optimal
empiric therapy, and provide impetus for and ascertain the
success of educational efforts promoting the judicious use
of antibiotics. Antimicrobial resistance is not uniform
across the United States (10). Nonsusceptibility to peni-
cillin among invasive pneumococcal isolates has been
shown to range from 15% to 35% among populations in
the Centers for Disease Control and Prevention’s (CDC)
national surveillance system (1).
The ideal method for accurate tracking of antimicro-
bial-resistance patterns in a community may be active, lab-
oratory-based surveillance systems that collect strains for
susceptibility testing in a reference laboratory. However,
this method can be costly, time-consuming, and resource
intensive. Alternative methods of measuring local drug-
resistant pneumococci that are less expensive and more
timely are needed. One alternative is to use aggregated
antibiograms. Astudy conducted by epidemiologists at the
Oregon Health Division found that aggregating existing
hospital antibiograms, also known as cumulative suscepti-
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cific, drug-resistant S. pneumoniae data when compared
with active-, laboratory-based surveillance, the standard
criterion for invasive disease. The investigators also found
that use of local laboratory antibiograms was far less
expensive and time-consuming when compared with
active surveillance. Whether Oregon’s results can be gen-
eralized is unknown; however, only 12 hospitals in one
city (Portland) were surveyed, and the percent of S. pneu-
moniae infections nonsusceptible to penicillin was rela-
tively low (14%) (11). We compared the two methods of
surveillance in a larger study that involved sites in geo-
graphically disparate areas and represented a larger frac-
tion of the national population and varying degrees of drug
resistance across the United States. Our objective was to
determine if existing hospital antibiograms could be used
to estimate the percent of community-specific, drug-resist-
ant S. pneumoniae in multiple sites. 
Methods
We compared the proportions of drug-resistant S. pneu-
moniae isolates reported by participating clinical laborato-
ries from the Active Bacterial Core Surveillance (ABCs)
sites to proportions obtained by aggregation of existing
antibiograms produced by the same ABCs laboratories. 
Active Laboratory-Based Surveillance
ABCs, a laboratory-based active surveillance system in
CDC’s Emerging Infections Program, tracks invasive dis-
ease caused by S. pneumoniae and other bacterial
pathogens of public health importance (12). Surveillance
areas included in this analysis were: California (CA) (San
Francisco County), Connecticut (CT) (entire state),
Georgia (GA) (20-county area, including Atlanta),
Maryland (MD) (6-county area including Baltimore),
Minnesota (MN) (7 counties), New York (NY) (7 coun-
ties), Oregon (OR) (3-county area including Portland), and
Tennessee (TN) (5 counties). The total population under
surveillance was 17 million. A case of invasive pneumo-
coccal disease was defined as the isolation of S. pneumo-
niae from a normally sterile site (e.g., blood, cerebrospinal
fluid) from a surveillance area resident. Surveillance per-
sonnel routinely contacted all clinical microbiology labo-
ratories in their site to identify cases and conducted audits
every 6 months to ensure complete reporting.
Pneumococcal isolates collected through ABCs were
sent to reference laboratories for susceptibility testing by
broth microdilution according to the methods of the
National Committee for Clinical Laboratory Standards
(NCCLS) (13). Isolates were defined as susceptible, hav-
ing intermediate resistance, or resistant to agents tested
according to NCCLS definitions (14).
Antibiograms
We requested existing antibiograms from all clinical
laboratories participating in ABCs. The antibiograms were
to cover the most recent 12-month period for which com-
pleted data were available at the time of the inquiry (1997
for GA, TN, CA, MN, OR, MD, and CT; 1998 for NY).
Any identifying information (e.g., hospital name) obtained
during collection of antibiogram data was removed before
the data were forwarded to study investigators at CDC.
Surveillance personnel also used a standardized question-
naire to query each hospital’s infection control practitioner
or microbiology supervisor regarding the production and
distribution of local antibiograms and whether antibiogram
data included sterile isolates, nonsterile site isolates, or
duplicates isolates from a single patient.
We compiled total numbers of S. pneumoniae isolates
identified from the ABCs sites along with the percent of
intermediate and resistant isolates, focusing on nonsus-
ceptibility to penicillin, macrolides, and extended-spec-
trum cephalosporins (e.g., cefotaxime, ceftriaxone). We
defined nonsusceptible isolates as those that were of inter-
mediate and high-level resistance or that were simply
described as not susceptible to the antibiotic tested. We
aggregated data obtained from the participating hospitals
within each ABCs site to produce summary antimicrobial
susceptibility percentages. When generating tables com-
paring percent of nonsusceptible pneumococcal isolates
estimated by antibiograms and by ABCs, we used only
antibiogram data for the year in question (1997 for all
sites excluding New York [1998]); antibiograms covering
other periods were excluded from this portion of the
analysis. Also, we used only antibiograms that included
both the total number of isolates tested and the percent
nonsusceptible for each of the antibiotics evaluated; this
system allowed for aggregation of the laboratory’s data
with those from other laboratories. If only a subset of iso-
lates were tested against erythromycin and extended-spec-
trum cephalosporins, we excluded these results from the
aggregated total for erythromycin, cephalosporins, or
both. We also calculated the percent of laboratories that
included S. pneumoniae susceptibility testing to a variety
of other antimicrobial agents and the percent of laborato-
ries generating antibiograms that included susceptibility
testing of gram-negative bacteria.
To compare the proportions of resistant and susceptible
S. pneumoniae isolates detected by the two surveillance
methods, we examined the proportion of hospitals whose
aggregated antibiogram data fell within a range of ± 5%
and ± 10% compared with that detected through active sur-
veillance.
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Generation of Antibiograms
One hundred and forty-five ABCs laboratories com-
pleted the surveys; these laboratories conducted antibiotic
susceptibility and other testing for a total of 170 (85%) of
the 199 hospital laboratories participating in ABCs at the
time the study was undertaken. Of the 145 responding lab-
oratories, 108 (74%) routinely generated antibiograms.
The 108 antibiograms created include pneumococcal sus-
ceptibility testing results for 140 (70%) of the 199 ABCs
hospital laboratories. In-house microbiologists typically
generated the antibiograms (83%), while infection control
practitioners (7%) and pharmacists (10%) created the
remaining. Nearly all laboratories included both sterile site
(98%) and nonsterile site (92%) isolates in the antibi-
ograms. Ninety-five percent included inpatient, and 79%
included outpatient isolates. Forty-six laboratories (43%)
included duplicate isolates from individual patients in their
antibiograms. 
When asked how pneumococcal isolates with interme-
diate susceptibility were categorized, survey responders
stated that their laboratory characterized these isolates as
intermediate (37%), resistant (32%), susceptible (5%), and
nonsusceptible (22%). This question did not specify the
antibiotic tested. Only 25 (23%) laboratories generated
antibiograms that included data distinguishing isolates
intermediate and resistant to penicillin; 77% only indicat-
ed whether the isolates were susceptible or nonsusceptible. 
The average number of isolates included in the summa-
ry antibiograms was nearly double the number collected
through active surveillance; the mean number of pneumo-
coccal isolates (per site) tested for penicillin susceptibility
was 417 (range 69–850) for ABCs and 826 (range
383–1,291) for summary antibiograms. Hospitals (n=40)
that excluded duplicate isolates from antibiograms aver-
aged similar numbers of isolates (mean 89 isolates) tested
for penicillin susceptibility as did hospitals (n=34) whose
antibiograms included multiple isolates from a single
patient (mean number of isolates tested 88). 
Of the 140 hospital laboratories whose pneumococcal
antibiotic susceptibility testing results were summarized in
antibiograms, 96 (70%) created antibiograms with peni-
cillin-susceptibility results in a format that could be aggre-
gated for the year in question. The proportion of laborato-
ries in each site that generated usable penicillin susceptibil-
ity data ranged from 70% (MD) to 100% (NY and MN).
Antibiograms included susceptibility-testing results for
macrolides (63%) and third-generation cephalosporins
(57%). The proportion of laboratories for which this sus-
ceptibility information was in a format that could be aggre-
gated, however, was smaller for macrolides (44%) and
third-generation cephalosporins (39%). For the eight sites,
the proportion of penicillin-nonsusceptible isolates from
ABCs ranged from 14.5% (NY) to 38.4% (TN), whereas
antibiograms yielded a range of 18.5% (CA) to 41.7%
(TN) (Table 1). For all sites the overall proportion of iso-
lates nonsusceptible to penicillin according to antibiograms
was within 10 percentage points of the population- and lab-
oratory-based surveillance (ABCs); for six sites it was
within 5 percentage points. The proportion of penicillin-
nonsusceptible isolates for each site identified by antibi-
ograms was higher than that generated by ABCs (median
difference: 3.65%; range 8.6% to 1.8%). No correlation
existed between site-specific levels of penicillin resistance
and the magnitude of difference between site-specific peni-
cillin resistance identified by the two methods. 
The proportions of pneumococcal isolates nonsuscepti-
ble to a third-generation cephalosporin and to erythromy-
cin were lower than the proportion of penicillin-nonsus-
ceptible isolates, regardless of the method used (Tables 2
and 3). Similar to the results for penicillin, the percentage
of strains nonsusceptible to third-generation cephalosporins
or erythromycin as detected by antibiograms tended to be
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Table 1. Comparison of percent of Streptococcus pneumoniae isolates nonsusceptible to penicillin by site: active surveillance (ABCs) 
versus antibiogram 
Antibiogram  ABCs 
Site 
No. 
laboratories
a 
Non-
susceptible 
isolates 
Total no. 
isolates tested 
% non-
susceptible 
No. 
laboratories 
Non-
susceptible 
isolates 
Total no. 
isolates tested 
% non-
susceptible 
Difference in % 
nonsusceptible 
(antibiograms vs. 
ABCs) 
Connecticut  16  168  845  19.9  32  113  624  18.1  1.8 
California  9  107  577  18.5  10  30  184  16.3  2.2 
Oregon  9  115  550  20.9  15  32  178  18.0  2.9 
Tennessee  10  432  1,037  41.7  31  169  440  38.4  3.3 
Maryland  10  171  886  19.3  27  85  557  15.3  4.0 
Georgia  14  505  1,291  39.1  39  292  850  34.4  4.7 
New York  9  85  383  22.2  20  10  69  14.5  7.7 
Minnesota  19  315  1,037  30.4  25  95  435  21.8  8.6 
Total  96  1,898  6,606  28.7  199  826  3,337  24.8  Median: 3.65 
aOnly laboratories whose antibiograms covered the calendar year in question (1997 for all sites except New York [1998]) were compared to ABCs. greater than the percent nonsusceptible detected by ABCs.
In contrast, the range of the differences for third-genera-
tion cephalosporins and erythromycin detected by the two
surveillance methods was larger than the range of differ-
ences for penicillin as measured for each ABCs site. The
magnitude of the difference in overall susceptibility to
third-generation cephalosporins determined by the two
surveillance methods was <10% for seven of eight sites
and <5% for five sites. The magnitude of the difference in
susceptibility to erythromycin as determined by the two
surveillance methods was <10% for all sites and <5% for
only four sites. 
In addition to penicillin, cephalosporins, and
macrolides, submitted antibiograms included susceptibili-
ty testing results for a variety of other antibiotics that
included the following: trimethoprim/sulfamethoxazole
(35%), vancomycin (59%), clindamycin (47%), gen-
tamycin (3.9%), and one or more fluoroquinolones (14%).
Thirty-eight percent of antibiograms returned for analysis
also included antimicrobial susceptibility testing results
for various gram-negative bacteria.
Discussion 
The results of our study suggest that antibiograms may
be an adequate method for conducting drug-resistant S.
pneumoniae surveillance for many health departments,
illustrating the comparability of aggregated antibiograms
that include both sterile and nonsterile site isolates to
active, laboratory- and population-based surveillance for
invasive isolates. For more than half the comparisons
between the two methods, the difference in antibiotic
resistance detected was <5 percentage points, and for 23
(96%) of the 24 comparisons the difference was <10 per-
centage points. No significant differences in comparability
of the two methods were noted between high- and low-
resistance areas. This study indicates that antibiograms
may be an alternative tool for evaluating penicillin nonsus-
ceptibility in a region and validates the earlier findings of
the Oregon study, conducted in an area of relatively low
antibiotic resistance (11).
Although the estimates of level of resistance obtained
from antibiograms approximated that from ABCs, aggre-
gated antibiogram data tended to show a higher proportion
of nonsusceptible isolates within each site and for each
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Table 2. Comparison of percent of Streptococcus pneumoniae isolates nonsusceptible to third-generation cephalosporins by site:  
active surveillance (ABCs) versus antibiograms 
Antibiogram  ABCs 
Site 
No. 
laboratories
a 
Non-
susceptible 
isolates 
Total  no. 
isolates 
tested 
% non-
susceptible 
No. 
laboratories 
Non-
susceptible 
isolates 
Total  no. 
isolates 
tested 
% non-
susceptible 
Difference in % 
nonsusceptible 
(antibiograms vs.
ABCs) 
Tennessee  10  54  357  15.1  31  114  440  25.9  –10.8 
New York  3  2  84  2.4  20  5  69  7.2  –4.8 
California  4  14  412  3.4  10  15  184  8.1  –4.7 
Connecticut  5  19  267  7.1  32  73  624  11.7  –4.6 
Oregon  6  34  419  8.1  15  14  178  7.9  0.2 
Maryland  5  53  476  11.1  27  48  557  8.6  2.5 
Minnesota  7  104  543  19.2  25  60  435  13.8  5.4 
Georgia  14  222  1,272  17.5  39  102  850  12.0  5.5 
Total   54  502  3,830  13.1  199  431  3,337  12.9  Median: –2.25 
aOnly laboratories whose antibiograms covered the calendar year in question (1997 for all sites except New York [1998]) were compared to ABCs. 
Table 3. Comparison of percent of Streptococcus pneumoniae isolates nonsusceptible to erythromycin by site: active surveillance 
(ABCs) versus antibiogram 
Antibiogram  ABCs 
Site 
No. 
laboratories
 a 
Non-
susceptible 
isolates 
Total. 
isolates 
tested 
% non-
susceptible 
No. 
laboratories 
Non-
susceptible 
isolates 
Total 
isolates 
tested 
% non-
susceptible 
Difference in 
% nonsusceptible 
(antibiogram vs. 
ABCs) 
Georgia  10  178  805  22.1  39  207  850  24.4  -2.3 
Tennessee  8  133  460  28.9  31  113  440  25.7  3.2 
Oregon  6  57  405  14.1  15  18  178  10.1  4.0 
Maryland  7  64  596  10.7  27  35  557  6.3  4.4 
New York  4  23  128  11.7  20  4  69  5.8  5.9 
California  9  92  577  15.9  10  15  184  8.2  7.7 
Minnesota  10  140  684  20.5  25  55  435  12.6  7.9 
Connecticut  7  58  287  20.2  32  65  624  10.4  9.8 
Total  61  737  3,942  18.7  199  512  3,337  15.3  Median: 5.15 
aOnly laboratories whose antibiograms covered the calendar year in question (1997 for all sites except New York [1998]) were compared to ABCs. antibiotic evaluated. This trend is likely due to the inclu-
sion of nonsterile (noninvasive) site isolates. In studies
from centers that include both sterile and nonsterile iso-
lates, nonsterile site isolates have been found to be equal-
ly or more resistant (15–17). The reason for this difference
is unclear but may reflect differences in serotype distribu-
tion between strains causing invasive and noninvasive dis-
ease. Disparity in results between clinical and reference
laboratories could also contribute to this trend; use of the
E test (AB Diodisk, Solna, Sweden) by clinical laborato-
ries might vary from the referent method (broth microdilu-
tion) by one half or one dilution (18). In this study, we
were unable to examine the role of laboratory error or dif-
ferences in susceptibility-testing methods as a reason for
differences in results from antibiograms compared with
those from active surveillance. 
Compared to penicillin, differences between the two
surveillance methods were greater for extended-spectrum
cephalosporins and erythromycin. This finding may be
because of smaller numbers of isolates included in the
antibiograms, fewer laboratories that included susceptibil-
ity testing of S. pneumoniae to these antibiotics, or greater
disagreement between clinical and reference laboratory
results. We could not include antibiogram-susceptibility
testing results for some hospital laboratories because only
a subset of the pneumococcal isolates that were tested for
penicillin nonsusceptibility were also tested for suscepti-
bility against third-generation cephalosporins (20 laborato-
ries) and erythromycin (13 laboratories). The potential
explanations for why these laboratories tested only a sub-
set of pneumococcal isolates (i.e., only penicillin-nonsus-
ceptible isolates were tested) against the same antibiotics
were not indicated on the antibiograms. 
We chose to evaluate the comparability of the two sur-
veillance methods by observing how often the percent non-
susceptible isolates estimated by aggregated antibiograms
differed by <5 and 10 percentage points from that estimat-
ed by ABCs active surveillance. As there exists no stan-
dardized or absolute level of antimicrobial drug resistance
that would dictate a change in empiric treatment of pneu-
mococcal infections, we chose a priori two conservative
thresholds of difference. A healthcare provider may not
modify empiric therapy based on the differences found in
our study, and the magnitude of differences reported here
are likely not relevant from a public health perspective.
Trends of pneumococcal antibiotic resistance over time
may be of more clinical and epidemiologic relevance than
an absolute level. Knowledge of local trends may help
communities assess regional antibiotic use and evaluate
the effects of local educational measures promoting the
judicious use of antibiotics. As this study did not span mul-
tiple years, we could not document the ability of antibi-
ograms to detect trends. However, given that sentinel sur-
veillance conducted in ABCs sites has been shown to
detect pneumococcal resistance trends over time (19) and
that in our study antibiograms provided site-specific point
estimates of antibiotic resistance similar to those measured
by active surveillance, antibiograms may be able to follow
trends in pneumococcal antimicrobial resistance at the
local level.
Drawbacks to this surveillance method include the
inability to evaluate resistance to multiple drugs.
Relatively few drugs can be evaluated because of laborato-
ry variations in antibiotics selected for susceptibility test-
ing by antibiograms. Health departments that wish to mon-
itor emerging resistance patterns to antibiotics, such as
vancomycin or fluoroquinolones, might consider a method
other than aggregated susceptibility tables, or they might
encourage hospital laboratories within a defined communi-
ty to standardize their susceptibility panels to facilitate
aggregation of results. Another limitation of antibiograms
is the inability to distinguish between intermediate- and
high-level resistance to penicillin; 77% of antibiograms in
our study expressed resistance as percent nonsusceptible
rather than distinguishing between intermediate and resist-
ant isolates. This distinction has become relevant for treat-
ment of some infections. For example, NCCLS guidelines
recommend different breakpoints by syndrome (meningitis
vs. nonmeningitis) for some agents (20). Aggregating
antibiograms is useful for infections that are generally
community-acquired, but antimicrobial resistance in hos-
pital-acquired infections should be evaluated based on the
knowledge of the particular institution’s flora. Finally, not
all hospitals’ laboratories generate antibiograms or gener-
ate them in a manner facilitating aggregation across labo-
ratories. However, we demonstrated the comparability of
the two surveillance methods despite the fact that the peni-
cillin-nonsusceptibility results, as measured by antibi-
ograms, was known for only 96 (48%) of the 199 ABCs
hospital laboratories.
This study should help clinicians and public health per-
sonnel in state or local health departments determine
which surveillance tool for obtaining estimates of antibi-
otic-resistant S. pneumoniae is best suited to their specif-
ic region or community by providing background infor-
mation on two alternative systems; the benefits and limi-
tations of each system may be reviewed to determine the
most useful and practical surveillance tool for a particular
region. Antibiograms are relatively inexpensive and easy
to use. Although not measured in our study, epidemiolo-
gists in Oregon found that the cost of active surveillance
was approximately 70 times that of aggregating antibi-
ograms for the three-county study area (11); the high cost
of this type of surveillance, however, is partially due to
the fact that ABCs is an integrated system that accom-
plishes multiple objectives in addition to susceptibility
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laboratories routinely generate antibiograms; therefore,
obtaining this information is relatively easy and within the
capacity of local health departments. Active surveillance,
on the other hand, excludes duplicate isolates for a single
patient or infection and is able to provide extensive addi-
tional information such as risk factors for resistant infec-
tions, outcome data, and other laboratory testing such as
serotype determination. Active surveillance also limits
case and isolate collection to persons who are residents of
the defined surveillance area, allowing for calculation of
rates of disease. Furthermore, active surveillance provides
individual patient-level data, allowing assessment of the
impact of specific interventions such as pneumococcal
conjugate vaccination of infants and young children.
Attainment of patient-level data through active surveil-
lance also permits detection of possible changes in the
incidence of resistant pneumococcal infections (e.g.,
because of a general decrease in cases of pneumococcal
infection among children receiving pneumococcal conju-
gate vaccine) that might go unnoticed if only the propor-
tion of resistant isolates were tracked (i.e., as done by
antibiograms).
Increasing antibiotic drug resistance is a problem that is
global in scale and that has practical implications for the
treatment and outcome of invasive infections from S.
pneumoniae and other bacteria of public health impor-
tance. Clinicians and researchers are now acknowledging
the importance of preventing resistant infections through
appropriate use of antibiotics and vaccines. Surveillance
data are needed to monitor the success of these campaigns
and to raise awareness of the problem. Because most local
laboratories generate antibiograms routinely, collecting
aggregating antibiogram data is an inexpensive and readi-
ly available method of measuring local antibiotic resist-
ance levels. Although providing less information than
active surveillance, aggregated antibiogram data are a gen-
erally accurate way for health departments to generate
needed community-specific estimates of pneumococcal
resistance. 
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